Key Documents

View All Documentation

L0420000

Levodropropizine

Name: Levodropropizine
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(2S)-3-(4-Phenyl-1-piperazinyl)-1,2-propanediol

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₃H₂₀N₂O₂

CAS Number:

99291-25-5

Molecular Weight:

236.31

UNSPSC Code:

41116107

NACRES:

NA.24

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

levodropropizine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N1(CCN(CC1)c2ccccc2)C[C@H](O)CO

InChI

1S/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2/t13-/m0/s1

InChI key

PTVWPYVOOKLBCG-ZDUSSCGKSA-N

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levodropropizine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under Levodropropizine

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 + P330 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment.

C Bruschi et al.

Pulmonary pharmacology & therapeutics, 16(4), 231-236 (2003-07-10)

To evaluate whether the peripherally acting antitussive levodropropizine could affect the respiratory drive and the breathing pattern, we performed a double-blind, randomised, cross-over trial in 12 healthy volunteers and 12 patients with chronic respiratory impairment associated with chronic obstructive pulmonary

Levodropropizine reduces capsaicin- and substance P-induced plasma extravasation in the rat trachea.

I Yamawaki et al.

European journal of pharmacology, 243(1), 1-6 (1993-10-12)

We investigated the effect of the non-opioid, peripherally acting antitussive agent levodropropizine to reduce neurogenic plasma extravasation in the rat trachea. Levodropropizine (10, 50 and 200 mg/kg) reduced in a dose-dependent manner the extravasation of Evans blue dye evoked by

Efficacy and tolerability of levodropropizine and dropropizine in children with non-productive cough.

G Banderali et al.

The Journal of international medical research, 23(3), 175-183 (1995-05-01)

The antitussive efficacy and tolerability of dropropizine and of its enantiomer levodropropizine were evaluated in children with non-productive cough; 258 were evaluable for tolerability and 254 for efficacy. Patients randomly received either 1 mg/kg dropropizine or 2 mg/kg levodropropizine orally

View All Related Papers

Global Trade Item Number

SKU	GTIN
L0420000	04061833945766